HumaLYM
Alternative Names: Anti-CD20 monoclonal antibody - IntracelLatest Information Update: 25 Nov 2021
At a glance
- Originator Intracel Corporation
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Non-Hodgkin's lymphoma in USA (unspecified route)
- 18 Jul 2000 New profile
- 18 Jul 2000 Preclinical development for Non-Hodgkin's lymphoma in USA (Unknown route)